Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer

• Egile Nagusiak: Yusuke Kobayashi (Egilea), Takashi Takeda (Egilea), Haruko Kunitomi (Egilea), Fumiko Chiwaki (Egilea), Masayuki Komatsu (Egilea), Shimpei Nagai (Egilea), Yuya Nogami (Egilea), Kosuke Tsuji (Egilea), Kenta Masuda (Egilea), Hideaki Ogiwara (Egilea), Hiroki Sasaki (Egilea), Kouji Banno (Egilea), Daisuke Aoki (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

In the field of drug repurposing, the use of statins for treating dyslipidemia is considered promising in ovarian cancer treatment based on epidemiological studies and basic research findings. Biomarkers should be established to identify patients who will respond to statin treatment to achieve clini...